Royal Free London's National Fabry Service has served as NICE's appointed clinical expert for every UK Fabry appraisal on record, evidence of how concentrated UK Fabry disease clinical authority actually is.
UK Fabry disease expertise is concentrated in five NHS lysosomal storage disorder referral centres: Guy's and St Thomas'/King's College London, Manchester, Addenbrooke's Cambridge, Birmingham, and Edinburgh. These centres carry NHS Highly Specialised Service commissioning for Fabry disease diagnosis, treatment initiation, and long-term outcomes tracking through the UK Fabry Outcome Survey. Royal Free London's National Fabry Service sits at the centre of that structure. NICE named it the appointed clinical expert for migalastat's Highly Specialised Technology appraisal (HST4, 2017) and again for pegunigalsidase alfa's technology appraisal (TA915), the two most recent formal HTA decisions in UK Fabry disease. That repeated appointment does not happen without an established position in national referral and evidence generation. Our KOL Universe gate (K1) starts by mapping this institutional structure before any single physician is scored.
The HEK cell-based assay confirming migalastat eligibility runs at four NHS genetics laboratories: Royal Free, Addenbrooke's, Manchester, and Birmingham/Sheffield. That distribution matters for tiering, since a centre offering both clinical management and amenable-mutation testing carries different institutional weight than one that refers testing elsewhere. Our Tier Classification gate (K2) scores that distinction directly, alongside NICE-appointed-expert status and UK Fabry Outcome Survey contribution. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live NHS service specifications and NICE appraisal documentation, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a centre with no real influence over NICE precedent or prescribing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The UK Fabry disease referral network — five named centres, one NICE-appointed expert
| Centre | City | Role in National Network |
|---|---|---|
| Royal Free London | London | National Fabry Service; NICE's appointed clinical expert for HST4 and TA915; HEK amenable-mutation assay laboratory |
| Guy's and St Thomas'/King's College London | London | NHS lysosomal storage disorder referral centre |
| Manchester | Manchester | NHS lysosomal storage disorder referral centre; HEK amenable-mutation assay laboratory |
| Addenbrooke's Cambridge | Cambridge | NHS lysosomal storage disorder referral centre; HEK amenable-mutation assay laboratory |
| Birmingham | Birmingham | NHS lysosomal storage disorder referral centre; HEK amenable-mutation assay laboratory (Birmingham/Sheffield) |
| Edinburgh | Edinburgh | NHS lysosomal storage disorder referral centre |
Sources: NHS England Highly Specialised Services lysosomal storage disorder service specification; NICE HST4 migalastat evidence summary (2017); NICE TA915 pegunigalsidase alfa appraisal document; UK Fabry Outcome Survey 2023.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The five-centre NHS LSD referral network
- Royal Free London's repeated NICE-appointed-expert role across HST4 and TA915
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- NICE-appraisal-expert status and HEK-assay-lab capability as weighting inputs
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live NHS and NICE document cross-checks
- why no placeholder centre ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration around a single NICE-appointed expert, not scattergun individual outreach, is the variable this workbook sizes first
- Pressure-tested against Royal Free London's repeated NICE-appointed-expert role before the rest of the workbook is built out
- Every UK Fabry disease institution sized and sourced from NHS and NICE documentation
- The five-centre NHS LSD network as the sizing anchor
- Universe boundaries: NICE-appointed expert versus a high-volume prescribing centre
- Institutional-influence scoring across NICE-appointed-expert status and HEK-assay capability
- What separates a Tier 1 institution from a routine prescribing centre
- Influence inputs: NICE appraisal-expert appointments, UK FOS registry contribution, institutional role
- Cross-checked against independent NHS and NICE documentation
- Readiness scoring and channel recommendations per institution
- Sequencing implications for MSL deployment
- Territory-to-centre coverage map across London, Manchester, Cambridge, Birmingham, and Edinburgh
- Where current MSL deployment has gaps
- Reach for institutions active beyond the UK, across wider European Fabry referral networks
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from published NHS service specifications and NICE appraisal documentation, not secondary summaries. No institution or KOL name ships without a verification tag.
UK Fabry disease KOL sources: NHS England Highly Specialised Services lysosomal storage disorder service specification, NICE HST4 migalastat evidence summary (2017), NICE TA915 pegunigalsidase alfa appraisal document, and UK Fabry Outcome Survey 2023 institutional contributor list.
- Referral centre list verified against NHS England Highly Specialised Services lysosomal storage disorder service specification
- Royal Free London's appointed-clinical-expert role verified against the published NICE HST4 (2017) and TA915 appraisal documents
- HEK assay laboratory list verified against NHS genetics laboratory service documentation
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK Fabry disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.